What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Pathology, Cancer research, Adenocarcinoma, Carcinoma and Internal medicine.
Hitoshi Tsuda specializes in Pathology, namely Immunohistochemistry.
The study incorporates disciplines such as Carcinogenesis, Tumor suppressor gene, Mutation, Oncogene and Gene duplication in addition to Cancer research.
His Adenocarcinoma study incorporates themes from Survival rate, Stomach, Anaplastic lymphoma kinase, KRAS and Cytokeratin.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
His studies deal with areas such as Surgery and Biopsy, Radiology as well as Breast cancer.
His most cited work include:
- KIF5B-RET fusions in lung adenocarcinoma. (603 citations)
- Actinin-4, a Novel Actin-bundling Protein Associated with Cell Motility and Cancer Invasion (405 citations)
- Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells (363 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Pathology, Internal medicine, Breast cancer, Oncology and Cancer.
Hitoshi Tsuda has included themes like Fluorescence in situ hybridization, Cancer research and Adenocarcinoma in his Pathology study.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
The Breast cancer study combines topics in areas such as Surgical oncology, Surgery and Biopsy, Radiology.
He combines subjects such as Neoadjuvant therapy, Pathological, Regimen, Lymph node and Survival analysis with his study of Oncology.
His Cancer research integrates issues from Molecular biology and Gene.
He most often published in these fields:
- Pathology (38.60%)
- Internal medicine (37.50%)
- Breast cancer (33.46%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (37.50%)
- Oncology (29.41%)
- Breast cancer (33.46%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer research and Cancer.
Hitoshi Tsuda studied Internal medicine and Gastroenterology that intersect with Clinical significance.
His Oncology research is multidisciplinary, relying on both Cyclophosphamide, Chemotherapy, Adjuvant therapy, Regimen and Ovarian cancer.
His biological study spans a wide range of topics, including Surgical oncology, Metastasis and Radiology.
His Cancer research research incorporates themes from Immunohistochemistry, Gene knockdown, Embryonal carcinoma, Survival rate and Intratubular germ cell neoplasia.
His Immunohistochemistry research is classified as research in Pathology.
Between 2017 and 2021, his most popular works were:
- The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). (28 citations)
- JAK2/STAT3 pathway as a therapeutic target in ovarian cancers (21 citations)
- Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer (12 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Oncology, Breast cancer, Pathological and Cancer research.
In the field of Internal medicine, his study on Hazard ratio, Colorectal cancer and Immunohistochemistry overlaps with subjects such as Clostridium difficile.
His Oncology study combines topics from a wide range of disciplines, such as Cyclophosphamide, Chemotherapy, Ovarian cancer and Clinical endpoint.
Hitoshi Tsuda interconnects Nomogram, Positron Emission Tomography-Computed Tomography and Fdg pet ct in the investigation of issues within Breast cancer.
His work carried out in the field of Cancer research brings together such families of science as Cell culture, Gene knockdown, Serous carcinoma, Cancer cell and Ovarian carcinoma.
His Carcinoma study introduces a deeper knowledge of Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
